A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
A phase 1/2 trial of Pembrolizumab, Atezolizumab, Bevacizumab in hepatocellular carcinoma, run by Tvardi Therapeutics, Incorporated, now recruiting.
Overview
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma is a phase 1/2 interventional study registered as NCT05440708 by Tvardi Therapeutics, Incorporated, with 193 participants planned, started 2023-03-23 and due to reach its primary completion in 2027-02-01. Interventions recorded: TTI-101, Pembrolizumab, Atezolizumab, Bevacizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
- TrialA Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
- TrialA Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
- TrialStudy of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
- TrialPhase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
- TrialA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Shares Atezolizumab, Bevacizumab.
- TrialIMbrave050
Shares Atezolizumab, Hepatocellular carcinoma.
- TrialS-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Shares Bevacizumab, Pembrolizumab.